Arvinas (ARVN) Doses First Patient in Phase 1/2 Trial of ARV-6723 for Advanced Solid Tumors

Arvinas Inc. (ARVN) said the first participant has been dosed in a Phase 1/2 clinical trial of ARV-6723, the company's first immuno-oncology clinical candidate, in patients with advanced solid tumors. The announcement was made on September 28, 2026. The early-stage trial marks Arvinas' expansion beyond its targeted protein degradation work in oncology into immuno-oncology. Dosing the first patient advances ARV-6723 into human testing. No financial terms, enrollment targets, or efficacy data were disclosed. Arvinas did not provide timelines for interim results.